Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Coho Relative Value Equity 2024 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Coho Relative Value Equity)

Primary Source Intelligence • Q2 2024 Letter Analysis

Coho Relative Value Equity Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Coho Relative Value Equity. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

YTD-1%

Digest Analysis

Quick Take

"Coho's value portfolio trails significantly in a market dominated by mega-cap tech concentration, but the firm sees this as creating an uncharacteristic valuation discount that will close as market breadth normalizes."

Executive Summary

Coho Partners maintains their value-focused approach despite a challenging first half of 2024, with their Relative Value Equity portfolio returning -1% year-to-date versus 15.3% for the S&P 500. The market continues to be narrowly led by mega-cap technology stocks, with NVIDIA alone accounting for nearly a third of S&P 500 returns. This concentration has created an uncharacteristically meaningful valuation discount for the Coho portfolio relative to the broader market. The manager believes this gap will close as the dominance of the Mag 7 naturally narrows due to the law of large numbers, leading to improved market breadth. They added to healthcare positions including Abbott Labs, Amgen, and UnitedHealth Group, finding value in a sector that has been a source of funding for technology rotation. Individual stock disappointments included CVS and Nike, while they eliminated Conagra in favor of Constellation Brands. The firm remains committed to their downside protection philosophy, viewing current conditions as reminiscent of the setup before the 2022 correction that validated their approach.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The manager demonstrates strong conviction in their value philosophy, explicitly stating they will not stray from their disciplines despite underperformance. They name specific positions and sizing decisions, make tactical swaps, and provide clear reasoning for their approach. However, the diversified nature of the portfolio and hedged language around timing caps the score below high conviction levels.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager acknowledges strong market performance but expresses concern about unsustainable concentration and elevated valuations. They expect normalization ahead but frame it positively for their strategy. Mixed signals with cautious optimism about their own prospects.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

The portfolio is positioned defensively with a focus on downside protection and value stocks that have underperformed. They're selectively adding to healthcare but maintaining their risk-conscious approach rather than chasing momentum.

Capital Deployment

25%

De-riskingDeploying

De-risking (25%)

The manager is selectively adding to healthcare positions (Abbott Labs, Amgen, UnitedHealth Group) and made a tactical swap from Conagra to Constellation Brands. This represents moderate, selective deployment rather than aggressive capital deployment or significant de-risking.

Forward Guidance

30%

CautiousExpansionary

Cautious (30%)

The manager is selectively deploying capital in healthcare and making tactical swaps like Conagra to Constellation Brands. They're not aggressively deploying but are making measured additions where they see value.

Language Signal

10%

BearishBullish

Bearish (10%)

Language is balanced with more risk-focused terms like concentration risks, elevated valuations, and myriad risks, offset by some opportunity language around value and normalization. Net slightly cautious tone.

Perceived Risk

72%

Low RiskElevated

Elevated Risk (72%)

The manager identifies multiple specific risks including market concentration, elevated valuations, geopolitical tensions, wars in Europe and Middle East, protectionism, ballooning deficits, and potential Fed missteps. They describe these as myriad risks and emphasize the importance of downside protection throughout the letter.

Opportunity Density

45%

ScarceAbundant

Selective (45%)

The manager sees selective opportunities in healthcare where they're adding positions, but characterizes the broader market as concentrated and expensive. They describe many stocks as being overlooked and left behind, suggesting a mixed opportunity environment requiring selectivity.

Time Horizon

72%

Short-TermLong-Term

Decade+ (72%)

The manager emphasizes their 25-year history and long-term philosophy, stating they will not stray from their disciplines. They expect the valuation gap to close in time and reference multi-year periods for thesis realization. They explicitly mention expecting low double-digit growth for many years to come for Constellation Brands.